Allarity Therapeutics IncNASDAQ:ALLRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.3700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3600/ 1
- Ask / Lots1.4200/ 8
- Open / Previous Close0.0000 / 1.3700
- Day Range---
- 52 Week Range
- Volume3,523
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALLR |
|---|---|---|
| 09:32 ET | 2045 | 1.4105 |
| 09:34 ET | 743 | 1.41 |
| 09:36 ET | 17291 | 1.42 |
| 09:38 ET | 125 | 1.4001 |
| 09:39 ET | 600 | 1.4001 |
| 09:41 ET | 1594 | 1.4083 |
| 09:43 ET | 3000 | 1.4099 |
| 09:48 ET | 230 | 1.41 |
| 09:50 ET | 1477 | 1.4005 |
| 09:52 ET | 27616 | 1.3883 |
| 09:54 ET | 2786 | 1.3805 |
| 09:57 ET | 1500 | 1.3801 |
| 10:01 ET | 1080 | 1.381 |
| 10:03 ET | 2520 | 1.3895 |
| 10:08 ET | 992 | 1.39 |
| 10:10 ET | 653 | 1.3999 |
| 10:15 ET | 300 | 1.3899 |
| 10:17 ET | 250 | 1.3888 |
| 10:19 ET | 2144 | 1.38 |
| 10:21 ET | 3975 | 1.3701 |
| 10:24 ET | 1400 | 1.38 |
| 10:28 ET | 150 | 1.4101 |
| 10:33 ET | 152 | 1.38 |
| 10:35 ET | 100 | 1.39 |
| 10:37 ET | 135 | 1.38 |
| 10:42 ET | 200 | 1.39 |
| 10:44 ET | 13805 | 1.37 |
| 10:51 ET | 412 | 1.37 |
| 10:53 ET | 225 | 1.37 |
| 10:55 ET | 5768 | 1.3701 |
| 11:00 ET | 23549 | 1.37 |
| 11:02 ET | 2918 | 1.37 |
| 11:04 ET | 500 | 1.37 |
| 11:06 ET | 1100 | 1.3793 |
| 11:08 ET | 5152 | 1.3715 |
| 11:11 ET | 3250 | 1.37 |
| 11:13 ET | 300 | 1.3615 |
| 11:15 ET | 275 | 1.41 |
| 11:18 ET | 100 | 1.4041 |
| 11:22 ET | 1800 | 1.4 |
| 11:24 ET | 825 | 1.41 |
| 11:26 ET | 400 | 1.4006 |
| 11:27 ET | 300 | 1.4003 |
| 11:31 ET | 341 | 1.3803 |
| 11:33 ET | 1000 | 1.38 |
| 11:36 ET | 5832 | 1.38 |
| 11:38 ET | 4022 | 1.3601 |
| 11:40 ET | 2035 | 1.3601 |
| 11:44 ET | 4750 | 1.41 |
| 11:45 ET | 300 | 1.41 |
| 11:47 ET | 200 | 1.3707 |
| 11:49 ET | 500 | 1.37 |
| 11:56 ET | 1753 | 1.37 |
| 12:03 ET | 107 | 1.3701 |
| 12:05 ET | 2768 | 1.38 |
| 12:07 ET | 200 | 1.3888 |
| 12:09 ET | 500 | 1.37 |
| 12:14 ET | 200 | 1.3735 |
| 12:16 ET | 124 | 1.385 |
| 12:18 ET | 1250 | 1.39 |
| 12:20 ET | 600 | 1.3899 |
| 12:21 ET | 800 | 1.3901 |
| 12:23 ET | 115 | 1.3989 |
| 12:32 ET | 1700 | 1.41 |
| 12:34 ET | 1625 | 1.41 |
| 12:36 ET | 450 | 1.4024 |
| 12:43 ET | 1674 | 1.38 |
| 12:45 ET | 1000 | 1.4173 |
| 12:48 ET | 300 | 1.4168 |
| 12:50 ET | 400 | 1.42 |
| 12:52 ET | 475 | 1.42 |
| 01:08 ET | 900 | 1.4199 |
| 01:10 ET | 100 | 1.4081 |
| 01:14 ET | 400 | 1.4 |
| 01:21 ET | 300 | 1.3901 |
| 01:26 ET | 618 | 1.3906 |
| 01:30 ET | 859 | 1.3701 |
| 01:35 ET | 491 | 1.42 |
| 01:39 ET | 175 | 1.4 |
| 01:44 ET | 200 | 1.41 |
| 01:48 ET | 2457 | 1.42 |
| 01:51 ET | 236 | 1.41 |
| 01:53 ET | 120 | 1.41 |
| 01:57 ET | 709 | 1.41 |
| 02:00 ET | 100 | 1.41 |
| 02:18 ET | 1100 | 1.39 |
| 02:20 ET | 1000 | 1.39 |
| 02:22 ET | 350 | 1.39 |
| 02:27 ET | 1000 | 1.3903 |
| 02:29 ET | 1100 | 1.39 |
| 02:31 ET | 689 | 1.41 |
| 02:40 ET | 100 | 1.395 |
| 02:44 ET | 300 | 1.405 |
| 02:49 ET | 785 | 1.4006 |
| 02:51 ET | 400 | 1.405 |
| 02:56 ET | 200 | 1.41 |
| 03:00 ET | 400 | 1.41 |
| 03:03 ET | 200 | 1.41 |
| 03:05 ET | 200 | 1.4005 |
| 03:07 ET | 300 | 1.41 |
| 03:16 ET | 1360 | 1.418 |
| 03:18 ET | 2133 | 1.408 |
| 03:21 ET | 100 | 1.41 |
| 03:25 ET | 2514 | 1.405 |
| 03:27 ET | 100 | 1.405 |
| 03:30 ET | 300 | 1.4016 |
| 03:34 ET | 372 | 1.4016 |
| 03:36 ET | 400 | 1.405 |
| 03:39 ET | 6272 | 1.421 |
| 03:43 ET | 1149 | 1.425 |
| 03:54 ET | 620 | 1.42 |
| 03:56 ET | 2379 | 1.42 |
| 03:57 ET | 4752 | 1.41 |
| 03:59 ET | 20204 | 1.37 |
Apr 17, 2024
*DJ Allarity Therapeutics Offering 5M Shrs at Assumed Public Offering Price of $2 Each, from 9:28AM ET on Wednesday Apr 17, 2024 by Dow Jones
9:28AM ET on Wednesday Apr 17, 2024 by Dow JonesAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1), from 9:10AM ET on Wednesday Apr 17, 2024 by Dow Jones
9:10AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 4, 2024
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split, from 9:15AM ET on Thursday Apr 04, 2024 by Dow Jones
9:15AM ET on Thursday Apr 04, 2024 by Dow Jones
Mar 27, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allarity Therapeutics Inc | 423.3K | 0.0x | --- |
Ampio Pharmaceuticals Inc | 397.4K | 0.0x | --- |
Myrexis Inc | 362.0K | 0.0x | --- |
Pharmagreen Biotech Inc | 464.6K | -0.6x | --- |
Life Stem Genetics Inc | 393.3K | -0.1x | --- |
Better Therapeutics Inc | 387.9K | 0.0x | --- |
Company Information
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
Contact Information
- Headquarters
- 24 School St., 2Nd FloorBOSTON, MA, United States 02108
- Phone
- 401-426-4664
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Gerald McLaughlin
- Chief Executive Officer
- Thomas Jensen
- Interim Chief Financial Officer, Director - Financial Reporting
- Joan Brown
- Chief Scientific Officer
- Steen Knudsen
- Independent Director
- Laura Benjamin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $423.3K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 309.0K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-4,118.49 |
Book Value | $-9.35 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
